Company Encyclopedia
View More
name
Cosunter
300436.SZ
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men’s health, and other fields. Fujian Cosunter Pharmaceutical Co., Ltd.
3.159 T
300436.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking183/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-47.59%E
    • Profit Margin-45.77%E
    • Gross Margin69.45%A
  • Growth ScoreD
    • Revenue YoY-8.17%D
    • Net Profit YoY11.71%C
    • Total Assets YoY0.38%C
    • Net Assets YoY-5.45%D
  • Cash ScoreD
    • Cash Flow Margin-218.50%D
    • OCF YoY-8.17%D
  • Operating ScoreD
    • Turnover0.28D
  • Debt ScoreD
    • Gearing Ratio69.18%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Fujian Cosunter Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 315.84 million compared to CNY 326.32 million a year ago. Net loss was CNY 111.58 million compared to CNY 70.64 million a year ago.Basic loss per share from continuing operations was CNY 0.7006 compared to CNY 0.4435 a year ago. Diluted loss per share from continuing operations was CNY 0.7006 compared to CNY 0.4435 a year ago.

    marketscreener·
    SZ
    300436
    +0.09%
    marketscreener·
    SZ
    300436
    +0.09%

    Cosunter: Net loss of RMB 44.8963 million in the third quarter, a decrease of 29.75%

    Cosunter announced that its revenue for the third quarter was 107 million yuan, a year-on-year decrease of 1.07%; the net loss was 44.8963 million yuan, a decrease of 29.75%. Revenue for the first three quarters was 316 million yuan, a year-on-year decrease of 3.21%; the net loss was 112 million yuan, a decrease of 57.96%

    Zhitong·
    SZ
    300436
    +0.09%
    Zhitong·
    SZ
    300436
    +0.09%

    Cosunter and ZZPZH established a pharmaceutical company with a registered capital of 50 million yuan

    According to the Qichacha APP, recently, Guangsheng Hehuang Pharmaceutical Co., Ltd. was established, with Huang Xiaohang as the legal representative and a registered capital of 50 million yuan. The business scope includes: wholesale of pharmaceuticals; operation of Class III medical devices; food sales; sales of health food; internet sales of food, etc. Qichacha's equity penetration shows that the company is jointly held by Guangsheng Tang and the wholly-owned subsidiary of Pianzaihuang, Fujian Pianzaihuang Health Technology Co., Ltd

    Zhitong·
    SZ
    300436
    +0.09%
    SH
    600436
    +0.12%
    Zhitong·
    SZ
    300436
    +0.09%
    SH
    600436
    +0.12%

    Cosunter and ZZPZH established a pharmaceutical company with a registered capital of 50 million

    According to Tianyancha's business information, recently, Guangsheng Hehuang Pharmaceutical Co., Ltd. was established, with Huang Xiaohang as the legal representative and a registered capital of 50 million RMB. The business scope includes drug wholesale, food sales, health food sales, internet sales of food, sales of special medical purpose formula foods, cosmetics wholesale, daily miscellaneous goods sales, and investment activities with its own funds. Shareholder information shows that the company is held by Guangsheng Tang and Fujian Pianzaihuang Health Technology Co., Ltd., a subsidiary of Pianzaihuang, with respective shares of 51% and 49%

    Zhitong·
    SZ
    300436
    +0.09%
    SH
    600436
    +0.12%
    Zhitong·
    SZ
    300436
    +0.09%
    SH
    600436
    +0.12%

    The three major A-share indices collectively rose at the midday break, with the innovative drug concept experiencing a surge

    36Kr learned that the three major indices of A-shares collectively rose during the midday break, with the Shanghai Composite Index up 0.1%, the Shenzhen Component Index flat, and the ChiNext Index up 0.22%; the innovative drug concept surged, with Cosunter and ALK hitting the daily limit; the retail and aviation sectors led the gains, with Nanning Department Store rising over 6% and Juneyao Airlines rising over 4%; the basic metals, diversified finance, and real estate sectors weakened, with Western Superconducting and Ganfeng Lithium falling over 6%, China National Petroleum Capital falling over 4%, and Binjiang Group falling over 3%

    36Kr·
    SZ
    002244
    -1.18%
    SZ
    300436
    +0.09%
    SZ
    002940
    -1.44%
    36Kr·
    SZ
    002244
    -1.18%
    SZ
    300436
    +0.09%
    SZ
    002940
    -1.44%
    © 2025 Longbridge｜Disclaimer